Inhibiting germination of Clostridium perfringens spores to reduce necrotic enteritis
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
University of Nevada, Las VegasThe University of Nevada, Las Vegas is a public research university offering comprehensive undergraduate, graduate, and professional programs. The institution is recognized for research initiatives, interdisciplinary curriculum, community partnerships, and diverse student support. UNLV provides resources spanning financial assistance, technology, career development, outreach, and research, advancing individual achievement and community engagement in a multicultural environment.
The University of Nevada, Las Vegas is a public research university offering comprehensive undergraduate, graduate, and professional programs. The institution is recognized for research initiatives, interdisciplinary curriculum, community partnerships, and diverse student support. UNLV provides resources spanning financial assistance, technology, career development, outreach, and research, advancing individual achievement and community engagement in a multicultural environment.
Publication Number
US-12144800-B2
Publication Date
2024-11-19
Expiration Date
Abstract
Provided herein are materials and methods useful for reducing, preventing, and/or inhibiting germination of C. perfringens spores, including methods for inhibiting C. perfringens germination to reduce necrotizing enteritis (NE, also referred to as necrotic enteritis) in animals. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Core Innovation
The invention relates to preventing a disease caused by infection by Clostridium perfringens in a subject by administering an effective amount of a compound having a structure represented by a formula. The compound structure includes selectable groups in the formula where Q and Z are selected from O, S, and NR3/NR4, and the substituents are further defined by selections for R3, R4, R1, R5a, R5b, R6, Cy1, Ar1, and Ar2, together with the constraint that each of R2a, R2b, R2c, and R2d is hydrogen.
The invention also provides inhibition of spore germination by contacting at least one Clostridium perfringens spore with a compound having the same general formula-defined structure. In this context, the selections for Q and Z, the optional presence and definitions for R3 and R4, and the range of substituents defined for R1, Cy1, Ar1, and Ar2 are tied to inhibiting germination of at least one Clostridium perfringens spore.
For preventing necrotic enteritis/necrotizing enteritis, the disclosure connects inhibition of spore germination to reduction of disease occurrence in the gut following administration in animals, including farm animals such as poultry. Representative compounds are provided, including benzoazole compounds such as MOB and 2-MTB, including salts and pharmaceutically acceptable salts.
Claims Coverage
The patent includes three independent claims. Across the independent claims, the coverage focuses on preventing a Clostridium perfringens infection-caused disease, inhibiting germination of Clostridium perfringens spores, and providing a feed composition containing a selected compound alongside a feed component.
Formula-defined compound for preventing infection-caused disease
Administering to a subject an effective amount of a compound having a structure represented by a formula with Q selected from O, S, and NR3; Z selected from O, S, and NR4; defined options for R3, R4, R1, R5a, R5b, R6, Cy1, Ar1, and Ar2, with each of R2a, R2b, R2c, and R2d being hydrogen, thereby preventing the disease caused by infection by Clostridium perfringens.
Formula-defined compound for inhibiting spore germination
Contacting at least one Clostridium perfringens spore with a compound having a structure represented by a formula with the same defined structural selections for Q, R3, Z, R4, R1, R5a, R5b, R6, Cy1, Ar1, and Ar2, and with each of R2a, R2b, R2c, and R2d being hydrogen, thereby inhibiting germination of at least one Clostridium perfringens spore.
Feed composition with selected compound
Providing a feed composition comprising a feed component and a compound selected from a set indicated by the claim.
Overall, the claim coverage centers on administering or contacting Clostridium perfringens-related targets using a tightly defined formula-defined benzoazole-compound structural space, and separately on incorporating a selected compound into a feed composition.
Stated Advantages
Prevents the disease caused by infection by Clostridium perfringens in a subject.
Inhibits germination of at least one Clostridium perfringens spore.
Reduction of disease occurrence in the gut following administration in animals, including farm animals such as poultry.
Reduction of necrotic enteritis occurrence.
Documented Applications
Preventing a disease caused by infection by Clostridium perfringens in a subject, including necrotic enteritis/necrotizing enteritis in the gut following administration in animals/farm animals.
Inhibiting germination of at least one Clostridium perfringens spore by contacting the spore with the formula-defined compound.
Use of a feed composition comprising a feed component and a compound selected from a defined set to inhibit spore germination in the gut and reduce necrotic enteritis occurrence.
Using the compounds in feed compositions for animals, including chicken, turkey, goose, duck, cow, sheep, horse, and pig.
Interested in licensing this patent?